Effects of TNFα inhibitors on adiposity and other cardiovascular risk factors: Implications for the cardiovascular prognosis in patients with rheumatoid arthritis

Expert Opinion on Drug Safety

Volumn 14, Issue 4, 2015, Pages 525-532

  Toussirot, Éric ^a,b,c,d  

^a UNIVERSITY HOSPITAL OF BESANÇON   (France)

^b UNIVERSITÉ DE FRANCHE COMTÉ   (France)

^c Université Bourgogne Franche Comté   (France)

^d LabEX LipSTIC   (France)

Author keywords

Adiposity; Atherogenic index; Cardiovascular risk factors; Lipids

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INFLIXIMAB; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; ANTIRHEUMATIC AGENT; TUMOR NECROSIS FACTOR ALPHA;

ABNORMAL SUBSTRATE CONCENTRATION IN BLOOD; ARTERIAL STIFFNESS; ARTERY DISEASE; ATHEROSCLEROSIS; BODY COMPOSITION; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; HUMAN; INFLAMMATION; LIPID STORAGE; METABOLIC SYNDROME X; OBESITY; PROGNOSIS; REGISTER; REVIEW; RHEUMATOID ARTHRITIS; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; BLOOD; CARDIOVASCULAR DISEASES; COMPLICATION; DRUG EFFECTS; PATHOPHYSIOLOGY; RISK FACTOR;

ADIPOSITY; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BODY COMPOSITION; CARDIOVASCULAR DISEASES; HUMANS; INFLAMMATION; LIPIDS; PROGNOSIS; RISK FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84924972212     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2015.1007041     Document Type: Review

References (61)

1. Nurmohamed MT.Cardiovascular risk in rheumatoid arthritis.Autoimmun Rev 2009; 8: 663-7
2. Soubrier M, Barber-Chamoux N, Tatar Z, et al.Cardiovascular risk in rheumatoid arthritis.Joint Bone Spine 2014; 81: 298-302
3. Solomon DH, Karlson EW, Rimm EB, et al.Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis.Circulation 2003; 107: 1303-7
4. Solomon DH, Kremer J, Curtis JR, et al.Explaining the cardiovascular risk associated with rheumatoid arthritis: traditional risk factors versus markers of rheumatoid arthritis severity.Ann Rheum Dis 2010; 69: 1920-5
5. Aviña-Zubieta JA, Choi HK, Sadatsafavi M, et al.Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-Analysis of observational studies.Arthritis Rheum 2008; 59: 1690-7
6. Liao K, Solomon DH.Traditional cardiovascular risk factors, inflammation and cardiovascular risk in rheumatoid arthritis.Rheumatology (Oxford) 2013; 52: 45-52
7. Choy E, Sattar N.Interpreting lipid levels in the context of high-grade inflammatory states with a focus on rheumatoid arthritis: a challenge to conventional cardiovascular risk actions.Ann Rheum Dis 2009; 68: 460-9
8. Giles JT, Ling SM, Ferrucci L, et al.Abnormal body composition phenotypes in older rheumatoid arthritis patients: association with disease characteristics and pharmacotherapies.Arthritis Rheum 2008; 59: 807-15
9. Westhovens R, Nijs J, Taelman V, et al.Body composition in rheumatoid arthritis.Br J Rheumatol 1997; 36: 444-8
10. Sattar N, McCarey DW, Capell H, et al.Explaining how " high-grade" systemic inflammation accelerates vascular risk in rheumatoid arthritis.Circulation 2003; 108: 2957-63
11. Carter AM.Inflammation, thrombosis and acute coronary syndromes.Diab Vasc Dis Res 2005; 2: 113-21
12. Avouac J, Allanore Y.Cardiovascular risk in rheumatoid arthritis: effects of anti-TNF drugs.Expert Opin Pharmacother 2008; 9: 1121-8
13. Hansson GK.Inflammation, atherosclerosis, and coronary artery disease.N Eng J Med 2005; 352: 1685-95
14. Boyer JF, Gourraud PA, Cantagrel A, et al.Traditional cardiovascular risk factors in rheumatoid arthritis: a meta-Analysis.Joint Bone Spine 2011; 78: 179-83
15. Rall LC, Roubenoff R.Rheumatoid cachexia: metabolic abnormalities, mechanisms and interventions.Rheumatology (Oxford) 2004; 43: 1219-23
16. Stavropoulos-Kalinoglou A, Metsios GS, Koutedakis Y, et al.Obesity in rheumatoid arthritis.Rheumatology (Oxford) 2011; 50: 450-62
17. Ferraccioli G, Gremese E.Adiposity, joint and systemic inflammation: the additional risk of having a metabolic syndrome in rheumatoid arthritis.Swiss Med Wkly 2011; 141: w13211
18. Dao HH, Do QT, Sakamoto J.Abnormal body composition phenotypes in Vietnamese women with early rheumatoid arthritis.Rheumatology (Oxford) 2011; 50: 1250-8
19. Toussirot E, Grandclement B, Gaugler B, et al.Serum adipokines and adipose tissue distribution in rheumatoid arthritis and ankylosing spondylitis A comparative study.Front Immunol 2013; 4: 453
20. Kaul S, Rothney MP, Peters DM, et al.Dual-energy X-ray absorptiometry for quantification of visceral fat.Obesity (Silver Spring) 2012; 20: 1313-18
21. Després JP.Body fat distribution and risk of cardiovascular disease: an update.Circulation 2012; 126: 1301-13
22. Giles JT, Bartlett SJ, Andersen R, et al.Association of body fat with C-reactive protein in rheumatoid arthritis.Arthritis Rheum 2008; 58: 2632-41
23. Berg AH, Scherer PE.Adipose tissue, inflammation, and cardiovascular disease.Circ Res 2005; 96: 939-49
24. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Phase III) final report.Circulation 2005; 106: 3143-421
25. Crowson CS, Myasoedova E, Davis JM, et al.Increased prevalence of metabolic syndrome associated with rheumatoid arthritis in patients without clinical cardiovascular disease.J Rheumatol 2011; 38: 29-35
26. Mottillo S, Filion KB, Genest J, et al.The metabolic syndrome and cardiovascular risk a systematic review and meta-Analysis.J Am Coll Cardiol 2010; 56: 1113-32
27. Peters MJ, Vis M, van Halm VP, et al.Changes in lipid profile during infliximab and corticosteroid treatment in rheumatoid arthritis.Ann Rheum Dis 2007; 66: 958-61
28. Popa C, van den Hoogen FH, Radstake TR, et al.Modulation of lipoprotein plasma concentrations during long-Term anti-TNF therapy in patients with active rheumatoid arthritis.Ann Rheum Dis 2007; 66: 1503-7
29. Popa C, Arts E, Fransen J, et al.Atherogenic index and high-density lipoprotein cholesterol as cardiovascular risk determinants in rheumatoid arthritis: the impact of therapy with biological.Mediators Inflamm 2012; 2012: 785946
30. Daïen CI, Duny Y, Barnetche T, et al.Effect of TNF inhibitors on lipid profile in rheumatoid arthritis: a systematic review with meta-Analysis.Ann Rheum Dis 2012; 71: 862-8
31. van Sijl AM, Peters MJ, Knol DL, et al.The effect of TNF-Alpha blocking therapy on lipid levels in rheumatoid arthritis: a meta-Analysis.Semin Arthritis Rheum 2011; 41: 393-400
32. Morris SJ, Wasko MC, Antohe JL, et al.Hydroxychloroquine use is associated with improvement in lipid profiles in rheumatoid arthritis patients.Arthritis Care Res (Hoboken) 2011; 63: 530-4
33. Voloshyna I, Seshadri S, Anwar K, et al.Infliximab reverses suppression of cholesterol efflux proteins by TNFalpha: a possible mechanism for modulation of atherogenesis.Biomed Res Int 2014; 2014: 312647
34. Engvall IL, Tengstrand B, Brismar K, et al.Infliximab therapy increases body fat mass in early rheumatoid arthritis independently of changes in disease activity and levels of leptin and adiponectin: a randomised study over 21 months.Arthritis Res Ther 2010; 12: R197
35. Serelis J, Kontogianni MD, Katsiougiannis S, et al.Effect of anti-TNF treatment on body composition and serum adiponectin levels of women with rheumatoid arthritis.Clin Rheumatol 2008; 27: 795-7
36. Metsios GS, Strapollos-Kalinoglou A, Douglas KM, et al.Blockade of tumour necrosis factor - A in rheumatoid arthritis : effects on components of rheumatoid cachexia.Rheumatology 2007; 46: 1824-7
37. Toussirot E, Mourot L, Dehecq B, et al.TNFalpha blockade for inflammatory rheumatic diseases is associated with a significant gain in android fat mass and has varying effects on adipokines: a 2-year prospective study.Eur J Nutr 2014; 53: 951-61
38. Hmamouchi I, Roux C, Paternotte S, et al.Early increase of abdominal adiposity in patients with spondyloarthritis receiving anti-Tumor necrosis factor-Alpha treatment.J Rheumatol 2014; 41: 1112-17
39. Marcora SM, Chester KR, Mittal G, et al.Randomised phase 2 trial of antitumor necrosis factor therapy for cachexia in patients with early rheumatoid arthritis.Am J Clin Nutr 2006; 84: 463-72
40. Tam LS, Tomlinson B, Chu TT, et al.Impact of TNF inhibition on insulin resistance and lipids levels in patients with rheumatoid arthritis.Clin Rheumatol 2007; 26: 1495-8
41. Stagakis I, Bertsias G, Karvounaris S, et al.Anti-Tumor necrosis factor therapy improves insulin resistance, beta cell function and insulin signaling in active rheumatoid arthritis patients with high insulin resistance.Arthritis Res Ther 2012; 14: R141
42. Gonzalez-Gay MA, De Matias JM, Gonzalez-Juanatey C, et al.Anti-Tumor necrosis factor-Alpha blockade improves insulin resistance in patients with rheumatoid arthritis.Clin Exp Rheumatol 2006; 24: 83-6
43. Hürlimann D, Forster A, Noll G, et al.Anti-Tumor necrosis factor-Alpha treatment improves endothelial function in patients with rheumatoid arthritis.Circulation 2002; 106: 2184-7
44. Irace C, Mancuso G, Fiaschi E, et al.Effect of anti TNF alpha therapy on arterial diameter and wall shear stress and HDL cholesterol.Atherosclerosis 2004; 177: 113-18
45. Mäki-Petäjä KM, Hall FC, Booth AD, et al.Rheumatoid arthritis is associated with increased aortic pulse-wave velocity, which is reduced by anti-Tumor necrosis factor-Alpha therapy.Circulation 2006; 114: 1185-92
46. Van Doornum S, McColl G, Wicks IP.Tumour necrosis factor antagonists improve disease activity but not arterial stiffness in rheumatoid arthritis.Rheumatology (Oxford) 2005; 44: 1428-32
47. Del Porto F, Laganá B, Lai S, et al.Response to anti-Tumour necrosis factor alpha blockade is associated with reduction of carotid intima-media thickness in patients with active rheumatoid arthritis.Rheumatology (Oxford) 2007; 46: 1111-15
48. Gonzalez-Juanatey C, Llorca J, Garcia-Porrua C, et al.Effect of antitumor necrosis factor alpha therapy on the progression of subclinical atherosclerosis in severe rheumatoid arthritis.Arthritis Rheum 2006; 55: 150-3
49. Mathieu S, Couderc M, Pereira B, et al.The effects of TNF-Alpha inhibitor therapy on arterial stiffness and endothelial dysfunction in rheumatoid arthritis: a meta-Analysis.Semin Arthritis Rheum 2013; 43: e1-2
50. Marks JL, Edwards CJ.Protective effect of methotrexate in patients with rheumatoid arthritis and cardiovascular comorbidity.Ther Adv Musculoskelet Dis 2012; 4: 149-57
51. Smolen JS, Landewé R, Breedveld FC, et al.EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological diseasemodifying antirheumatic drugs: 2013 update.Ann Rheum Dis 2014; 73: 492-509
52. Barnabe C, Martin BJ, Ghali WA.Systematic review and meta-Analysis: anti-Tumor necrosis factor alpha therapy and cardiovascular events in rheumatoid arthritis.Arthritis Care Res (Hoboken) 2011; 63: 522-9
53. Ljung L, Askling J, Rantapää-Dahlqvist S, et al.The risk of acute coronary syndrome in rheumatoid arthritis in relation to tumour necrosis factor inhibitors and the risk in the general population: a national cohort study.Arthritis Res Ther 2014; 16: R127
54. Desai RJ, RAo JK, Hansen RA, et al.Tumor necrosis factor-Alpha inhibitor treatment and the risk of incident cardiovascular events in patients with early rheumatoid arthritis : a nested case -control study.J Rheumatol 2014; 41: 2129-36
55. Dixon WG, Symmons DP.What effects might anti-TNF alpha treatment be expected to have on cardiovascular morbidity and mortality in rheumatoid arthritis? A review of the role of TNFalpha in cardiovascular pathophysiology.Ann Rheum Dis 2007; 66: 1132-6
56. Peters MJ, Symmons DP, McCarey D, et al.EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis.Ann Rheum Dis 2010; 69: 325-31
57. Metsios GS, Stavropoulos-Kalinoglou A, Veldhuijzen van Zanten JJ, et al.Rheumatoid arthritis, cardiovascular disease and physical exercise : a systematic review.Rheumatology (Oxford) 2008; 47: 239-48
58. Reiss AB, Carson SE, Anwar K, et al.Atheroprotective effects of methotrexate on reverse cholesterol transport proteins and foam cell transportation in human THP-1 monocyte/macrophages.Arthritis Rheum 2008; 58: 3675-83
59. Everett BM, Pradhan AD, Solomon DH, et al.Rationale and design of the Cardiovascular Inflammation Reduction Trial: a test of the inflammatory hypothesis of atherothrombosis.Am Heart J 2013; 166: 199-207
60. Meune C, Touzé E, Trinquart L, et al.Trends in cardiovascular mortality in patients with rheumatoid arthritis over 50 years: a systematic review and metaanalysis of cohort studies.Rheumatology (Oxford) 2009; 48: 1309-13
61. Norton S, Nikiphorou E, Carpenter L, et al.Reduced mortality risk in rheumatoid arthritis: findings from two UK inception cohorts.Arhritis Rheumatol 2014; 66(Suppl): S1226-7